Questcor Misses on Earnings, Revs - Analyst Blog

By
A A A

Questcor Pharmaceuticals Inc. ( QCOR ) reported first quarter 2013 adjusted earnings per share of 67 cents, up 15.5% from the year-ago period. Earnings were, however, well below the Zacks Consensus Estimate of 97 cents.

First quarter 2013 revenues climbed 41% to $135.1 million. Strong performance of H.P. Acthar Gel in the nephrotic syndrome (NS), dermatomyositis, polymyositis, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis (MS) relapses and infantile spasms (IS) indications contributed to the massive growth.  Revenues, however, missed the Zacks Consensus Estimate of $154 million.

In the first quarter of 2013, research and development (R&D) expenses were $10.8 million, up 90.5%. The increase was attributable to the company's efforts to develop its pipeline. Currently, Acthar is being studied for amyotrophic lateral sclerosis (ALS) and diabetic nephropathy.

In the reported quarter, general and administrative expenses were $12.5 million, up 130.6% and selling and marketing expenses were $35.5 million, up 63.3%.

Acthar, an injectable drug, is the lead product at Questcor. It is approved by the FDA for as many as 19 indications. The company shipped 4,830 vials of Acthar during the first quarter of 2013, up 17.5% year over year but down sequentially by 23.7%. However, in Apr 2013, Questcor made a record by shipping 2,550 vials of Acthar to its distributor in a single month. 

In the reported quarter, Acthar's new paid prescriptions were about 1,725 to 1,750, up 16% year over year.

Questcor carries a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. ( LCI ), Onyx Pharmaceuticals, Inc. ( ONXX ) and UCB ( UCBJF ) look more attractive with a Zacks Rank #1 (Strong Buy).



LANNETT INC (LCI): Free Stock Analysis Report

ONYX PHARMA INC (ONXX): Free Stock Analysis Report

QUESTCOR PHARMA (QCOR): Free Stock Analysis Report

UCB SA (UCBJF): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Earnings , Stocks

Referenced Stocks: IS , LCI , MS , NS , ONXX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

50%
69%
67%

Most Active by Volume

210,963,151
    $91.50 unch
174,438,291
  • $40.58 ▼ 3.58%
63,265,129
  • $5.335 ▼ 1.39%
59,537,138
  • $17 ▼ 0.23%
43,074,995
  • $39.71 ▼ 4.43%
40,415,935
  • $46.98 ▲ 0.64%
38,682,143
  • $101.776 ▼ 0.01%
29,330,461
  • $3.58 ▼ 1.51%
As of 9/19/2014, 01:36 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com